Platelet aggregation and von Willebrand factor in patients with artherial hypertension combined with osteoarthritis

Агрегация тромбоцитов и фактор Виллебранда у больных артериальной гипертензией в сочетании с остеоартрозом
Viktoriya Rodionova 1, Olena Khmel 1
More Detail
1 Department of occupational diseases and clinical immunology, State establishment «Dnipropetrovsk medical academy of Health Ministry of Ukraine», Dnipro, Ukraine
J CLIN MED KAZ, Volume 1, Issue 43, pp. 34-41. https://doi.org/10.23950/1812-2892-JCMK-00337
OPEN ACCESS 4805 Views 3687 Downloads
Download Full Text (PDF)

ABSTRACT

Objective: To investigate the platelet aggregation and level of von Willebrand factor in patients with hypertension and knee osteoarthritis.
Methods: The study involved 102 people: 29 patients with hypertension stage II combined with osteoarthritis stage II – main group; 29 patients with hypertension stage II – frst group of comparison, 24 patients with osteoarthritis stage II – second group of comparison. The control group consisted of 20 almost healthy persons. Methods: ambulatory blood pressure monitoring, optical platelet aggregation test (inducers of platelet aggregation – adenosine diphosphate, collagen, thrombin, ristocetin (2 micromole)).
Results: Von Willebrand factor was higher in patients with hypertension combined with osteoarthritis and in patients with isolated hypertension (182.6 [171.6 – 201.7] %, 184.8 [171.6 – 207.7] % respectively), compared to patients with osteoarthritis (167 [144.6 – 181.6] %) and the control group (163.4 [151.7 – 172.3] %) (p<0.05). The degree of platelet aggregation with adenosine diphosphate in patients with hypertension combined with osteoarthritis and in patients with hypertension had signifcant correlations with level of total cholesterol and daily index of systolic blood pressure (p <0.05)).
Conclusion: Von Willebrand factor, degree platelet aggregation induced by adenosine diphosphate, collagen and thrombin were higher in patients with hypertension combined with osteoarthritis and in patients with hypertension compared to both the group of patients with osteoarthritis and control group (p <0.05). The degree of platelet aggregation with adenosine diphosphate was influenced by the level of total cholesterol and daily index of systolic blood pressure, the degree of platelet aggregation with collagen was influenced by daily index of systolic blood pressure and daily index of diastolic blood pressure (p<0.05).
Keywords: hypertension, osteoarthritis, platelet aggregation, von Willebrand factor, ambulatory blood pressure monitoring

CITATION

Rodionova V, Khmel O. Platelet aggregation and von Willebrand factor in patients with artherial hypertension combined with osteoarthritis. Journal of Clinical Medicine of Kazakhstan. 2017;1(43):34-41. https://doi.org/10.23950/1812-2892-JCMK-00337

REFERENCES

  • Neal B. Blood Pressure Lowering Treatment Trials’ Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: result of prospectively designed over views of randomized trails. Lancet. 2000;355:1955-64.
  • Pharmacotherapy of arterial hypertension in accordance with the guidance of the joint national committee for the prevention, recognition and treatment of hypertension in 2014 (review of literature). Y. V. Verkhovodova, I.V. Kireev, M.G. Bakumenko, etc. Drugs - for people. Modern problems of pharmacotherapy and prescribing of drugs. Materials of the XXX All-Ukrainian scientific and practical conference, Kharkiv, 2014. H.: NFaU. 2014; 163-171.
  • Guideline for hypertension ed. by V.M. Kovalenko, E.P. Svischenko, Y.M. Sirenko. Kyiv . MORION, 2010; 491 p.
  • Svintsitsky I.A. Modern aspects of management in patients with hypertension. Practicing doctor. 2013; 3:63-69.
  • Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood pressure. 2013; 1;22(4):193-278.
  • A global brief on Hypertension. Silent killer, global public health crisis[Electronic resource] // WHO. - 2013. - access mode to the resource: http://apps.who.int/iris/bitstream/10665/7905/1/WHO_DCO_WHD_2013.2_eng.pdf.
  • Blikhar V.E. Treatment of patients with arterial hypertension and concomitant pathology. Medicine and education in Siberia. 2014; 1: 41-48.
  • Vizir M.O. Home blood pressure monitoring in clinical practice. M.A. Vizir, O.A. Kochubyey. The role and place of medicine in ensuring of human health in modern society: a collection of abstracts of scientific papers participants of the international scientific conference, Lviv, 31 January - 1 February 2014 - Lviv medical community. - 2014. - P. 16-17.
  • Rebrov A.P., Magdeeva I.A., Romanova V.V. Features of endothelial dysfunction in arterial hypertension in combination with gout or osteoarthritis. Bulletin of modern clinical medicine. 2011: 1(4):6-8.
  • Differentiated approach in the treatment of Gonarthrosis with anti-inflammatory drugs, depending on the mineral density of bone tissue. N.M. Shuba, Т.М. Tarasenko. Ukrainian rheumatological journal. 2015; 1: 42 - 49.
  • Flurbiprofen in the treatment of osteoarthritis T.S. Silantieva, G.P. Ivanova, T.M. Kostyuchenko et all. Ukrainian rheumatological journal. 2013; 1: 26 - 32.
  • Rodionov A.V. Non-steroidal anti-inflammatory drugs and arterial hypertension: the urgency of the problem and the tactics of patient management. Therapist. 2013; 2: 25-31.
  • Use of non-steroidal anti-inflammatory drugs in elderly people. V.B. Shatilo, L.A. Stadnyuk, E.A. Asanov, V.Y. Prikhodko. Distance learning. 2010; 2:14-19.
  • Eliseev MS, Barskova VG, Eliseyev MS. MELOXICAM: WHAT DO WE KNOW ABOUT CARDIOVASCULAR SAFETY?. Modern Rheumatology Journal. 2010; 14(1):79-83.
  • Recommendations of Ukrainian Association of Cardiology on prevention and treatment of hypertension. Guide to the National Programme for prevention and treatment of hypertension. Kyiv. 2011.
  • Arterial hypertension. Updated and adapted clinical guidelines based on evidence. Annex to the Order of the MOH Ukraine On approval and introduction of medical and technological documents for standardization of medical care in hypertension from May, 24, 2012 №384. Retrieved from www.moz.gov.ua/ua/portal/dn_20120524_384.html.
  • Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, Howell D. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis & Rheumatology. 1986; 1;29(8):1039-49.
  • Zhang W, Doherty M, Peat G, Bierma-Zeinstra SM, Arden NK, Bresnihan B, Herrero-Beaumont G, Kirschner S, Leeb BF, Lohmander LS, Mazières B. EULAR evidence based recommendations for the diagnosis of knee osteoarthritis. Annals of the rheumatic diseases. 2009; 17:8-18.
  • Annex to the Order of the MOH Ukraine On approval and introduction of medical and technological documents for standardization of medical care in rheumatology from October, 12, 2006 № 676. [in Ukrainian]. Retrieved from http://www.moz.gov.ua/ua/ portal/dn_20061012_676.html
  • Medvedev I.N. Rosuvastatin in reducing the risk of thrombotic danger in patients with arterial hypertension and dyslipidemia. Medical almanac. 2013; 4:105-108.
  • McManus DD, Freedman JE. MicroRNAs in platelet function and cardiovascular disease. Nature Reviews Cardiology. 2015; 1;12(12):711-7. http://www.nature.com/nrcardio/journal/v12/n12/full/nrcardio.2015.101.html
  • Medvedev I.N. Dynamics of platelet hemostasis activity in patients with arterial hypertension and dyslipidemia as a result of atorvastatin intake. Fundamental research. 2013; 9:84-88.
  • Khromylev A.V. Pathogenetic aspects of atherothrombotic risk in obesity and thrombophilia. Obstetrics, gynecology and reproduction. 2015; 3:45-52.
  • Belovol AN Tactics of management of patients with arterial hypertension: a view through the prism of cardiometabolic risk. Ukrainian Journal of Cardiology. 2007; 6:8-12.
  • Shanchenko S.A., Lipatova Т.Е. BMI and blood pressure level as factors influencing the elasticity of the vascular wall and endothelium-dependent dilatation in pregnant women [Electronic resource]. Cardiology. 2016. Mode access to the resource: http://medconfer.com/node/6481.
  • Delyagin V.M., Novikova T.A., Olimpieva S.P. Evidence-based analysis of the results of daily monitoring of blood pressure in children and adolescents. Systemic hypertension. 2011: 2: 60-66. 
  • Alexenko E.Y., Govorin A.V., Zwinger S.M. Nitroxide-producing endothelial function and platelet aggregation in patients with primary osteoarthritis. Bulletin of the East Siberian Scientific Center of the Siberian Branch of the Russian Academy of Medical Sciences. 2011; 1; 21-24.
  • Kurkina I.A. Hypercoagulation and thrombosis in patients with cirrhosis. Gastroenterology. 2015; 3:20-25.
  • Drobyshev V.A., Egorova E.A., Logachova G.S., Filatov O.M. Low-energy electromagnetic fields and radiation in correction of vascular and haemostasiological changes in patients with arterial hypertension with cervical dorsopathies [Electronic resource]. Medicine and Education in Siberia. 2015. - Mode access to the resource: http://ngmu.ru/cozo/mos/article/text_full.php?id=1757.
  • Kislyak O.A. Combined therapy: the key to successful control of hypertension for a practical physician. Consilium medicum. 2011; 13:90-93.